nach oben

Erschienen in:

18.09.2018 | Article

Dose-dependent effect of smoking on risk of coronary heart disease, heart failure and stroke in individuals with type 1 diabetes

verfasst von: Maija Feodoroff, Valma Harjutsalo, Carol Forsblom, Per-Henrik Groop, on behalf of the FinnDiane Study Group

Erschienen in: Diabetologia | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The aim of this study was to assess the potential dose-dependent effects of smoking on the risk of CHD, heart failure and stroke in individuals with type 1 diabetes.

Methods

The study included 4506 individuals with type 1 diabetes who were participating in the Finnish Diabetic Nephropathy (FinnDiane) study. Intensity of smoking was estimated by packs per day and cumulative smoking by pack-years. Cox regression analyses were used to estimate the risk of incident CHD, heart failure or stroke during follow-up.

Results

One pack per day significantly increased the risk of incident CHD in current smokers compared with never smokers (HR 1.45 [95% CI 1.15, 1.84]), after adjustment for age, sex, HbA_1c, hypertension, duration of diabetes and BMI. The risk of CHD in former smokers was similar to the risk in never smokers. The risk of incident heart failure was 1.43 (95% CI 1.03, 1.97) in current smokers per one pack per day and 1.37 (95% CI 1.05, 1.77) in former smokers, while the risk of incident stroke was 1.70 (95% CI 1.26, 2.29) and 1.49 (95% CI 1.14, 1.93), respectively. After further adjustments for lipids, however, the difference in the risk of heart failure in current and former smokers was no longer significant. Cumulative smoking data were similar to smoking intensity data.

Conclusions/interpretation

There is a dose-dependent association between smoking and cardiovascular disease in individuals with type 1 diabetes. In men in particular, the risk of incident stroke remains high even after smoking cessation and is increased in current and former smokers independently of other risk factors.

Nur mit Berechtigung zugänglich

Vazquez-Benitez G, Desai JR, Xu S et al (2015) Preventable major cardiovascular events associated with uncontrolled glucose, blood pressure, and lipids and active smoking in adults with diabetes with and without cardiovascular disease: a contemporary analysis. Diabetes Care 38:905–912CrossRef

Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW (2013) Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 368:1613–1624CrossRef

Pan A, Wang Y, Talaei M, Hu FB (2015) Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: a meta-analysis and systematic review. Circulation 132:1795–1804CrossRef

Moy CS, LaPorte RE, Dorman JS et al (1990) Insulin-dependent diabetes mellitus mortality. The risk of cigarette smoking. Circulation 82:37–43CrossRef

Rossing P, Hougaard P, Borch-Johnsen K, Parving HH (1996) Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ 313:779–784CrossRef

Chaturvedi N, Stevens L, Fuller JH (1997) Which features of smoking determine mortality risk in former cigarette smokers with diabetes? The World Health Organization Multinational Study Group. Diabetes Care 20:1266–1272CrossRef

Fuller JH, Stevens LK, Wang SL (2001) Risk factors for cardiovascular mortality and morbidity: the WHO Mutinational Study of Vascular Disease in Diabetes. Diabetologia 44(Suppl 2):S54–S64CrossRef

Orchard TJ, Olson JC, Erbey JR et al (2003) Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 26:1374–1379CrossRef

Klein BE, Klein R, McBride PE et al (2004) Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. Arch Intern Med 164:1917–1924CrossRef

10.

Soedamah-Muthu SS, Chaturvedi N, Toeller M et al (2004) Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB prospective complications study. Diabetes Care 27:530–537CrossRef

11.

Miller RG, Prince CT, Klein R, Orchard TJ (2009) Retinal vessel diameter and the incidence of coronary artery disease in type 1 diabetes. Am J Ophthalmol 147:653–660CrossRef

12.

Miller RG, Secrest AM, Ellis D, Becker DJ, Orchard TJ (2013) Changing impact of modifiable risk factors on the incidence of major outcomes of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 36:3999–4006CrossRef

13.

Gopal DM, Kalogeropoulos AP, Georgiopoulou VV et al (2012) Cigarette smoking exposure and heart failure risk in older adults: the health, aging, and body composition study. Am Heart J 164:236–242CrossRef

14.

Lind M, Bounias I, Olsson M, Gudbjornsdottir S, Svensson AM, Rosengren A (2011) Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet 378:140–146CrossRef

15.

Konduracka E, Cieslik G, Galicka-Latala D et al (2013) Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort study. Acta Diabetol 50:597–606CrossRef

16.

Woodward M, Lam TH, Barzi F et al (2005) Smoking, quitting, and the risk of cardiovascular disease among women and men in the Asia-Pacific region. Int J Epidemiol 34:1036–1045CrossRef

17.

O'Donnell MJ, Xavier D, Liu L et al (2010) Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 376:112–123CrossRef

18.

Secrest AM, Prince CT, Costacou T, Miller RG, Orchard TJ (2013) Predictors of and survival after incident stroke in type 1 diabetes. Diab Vasc Dis Res 10:3–10CrossRef

19.

Lightwood JM, Glantz SA (1997) Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation 96:1089–1096CrossRef

20.

Critchley JA, Capewell S (2003) Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 290:86–97CrossRef

21.

Jha P, Ramasundarahettige C, Landsman V et al (2013) 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 368:341–350CrossRef

22.

Thomas DC (2014) Invited commentary: is it time to retire the “pack-years” variable? Maybe not. Am J Epidemiol 179:299–302CrossRef

23.

Lubin JH, Couper D, Lutsey PL, Woodward M, Yatsuya H, Huxley RR (2016) Risk of cardiovascular disease from cumulative cigarette use and the impact of smoking intensity. Epidemiology 27:395–404CrossRef

24.

McEvoy JW, Blaha MJ, DeFilippis AP et al (2015) Cigarette smoking and cardiovascular events: role of inflammation and subclinical atherosclerosis from the MultiEthnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 35:700–709CrossRef

25.

Nance R, Delaney J, McEvoy JW et al (2017) Smoking intensity (pack/day) is a better measure than pack-years or smoking status for modeling cardiovascular disease outcomes. J Clin Epidemiol 81:111–119CrossRef

26.

Thorn LM, Forsblom C, Fagerudd J et al (2005) Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 28:2019–2024CrossRef

27.

Finnish Hospital league (1983) Toimenpidenimikkeistö 1983. (Classification of procedures 1983, in Finnish). Finnish Hospital League, Helsinki

28.

Hertzmark E, Spiegelman D. 2017 The SAS METAANAL Macro. Available at https://www.hsph.harvard.edu/donna-spiegelman/software/metaanal/

29.

Mons U, Muezzinler A, Gellert C et al (2015) Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ 350:h1551CrossRef

30.

Feodoroff M, Harjutsalo V, Forsblom C et al (2016) Smoking and progression of diabetic nephropathy in patients with type 1 diabetes. Acta Diabetol 53:525–533CrossRef

31.

Borch-Johnsen K, Kreiner S (1987) Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) 294:1651–1654CrossRef

32.

Fisher SD, Zareba W, Moss AJ et al (2000) Effect of smoking on lipid and thrombogenic factors two months after acute myocardial infarction. Am J Cardiol 86:813–818CrossRef

33.

Craig WY, Palomaki GE, Haddow JE (1989) Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ 298:784–788CrossRef

34.

Gerber PA, Locher R, Schmid B, Spinas GA, Lehmann R (2013) Smoking is associated with impaired long-term glucose metabolism in patients with type 1 diabetes mellitus. Nutr Metab Cardiovasc Dis 23:102–108CrossRef

35.

McMurray JJ, Stewart S (2000) Epidemiology, aetiology, and prognosis of heart failure. Heart 83:596–602CrossRef

36.

Hagg S, Thorn LM, Forsblom CM et al (2014) Different risk factor profiles for ischemic and hemorrhagic stroke in type 1 diabetes mellitus. Stroke 45:2558–2562CrossRef

Titel: Dose-dependent effect of smoking on risk of coronary heart disease, heart failure and stroke in individuals with type 1 diabetes
verfasst von: Maija Feodoroff
Valma Harjutsalo
Carol Forsblom
Per-Henrik Groop
on behalf of the FinnDiane Study Group
Publikationsdatum: 18.09.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 12/2018
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-018-4725-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Nierenkarzinom | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Dose-dependent effect of smoking on risk of coronary heart disease, heart failure and stroke in individuals with type 1 diabetes

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Update Innere Medizin

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2018

Gestational weight gain: an ounce of prevention is still worth a pound of cure

Genome-wide profiling of histone H3K27 acetylation featured fatty acid signalling in pancreatic beta cells in diet-induced obesity in mice

A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin

Up Front

Which is more important for cardiometabolic health: sedentary time, higher intensity physical activity or cardiorespiratory fitness? The Maastricht Study

Fifty years of pancreatic islet pathology in human type 1 diabetes: insights gained and progress made

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Update Innere Medizin